secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0000950170-23-009977
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete
-----------------------------------------------------------------------

- Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.
- Cash, equivalents & short-term investments $101.2M as of Dec 31, 2022.
- R&D expenses $37.7M in 2022, up 34% due to STRIDE and STRIDE AHEAD studies.
- Pivotal STRIDE study (PMM) enrolled target 200 patients; topline results expected Q4 2023.
- Plans to study mavodelpar in PMM due to nDNA defects and advance LC-FAOD program into Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/0000950170-23-009977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/rphm-20230327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer